Biofinity Toric Multifocal Contact Lens
FDA Device Recall #Z-2166-2025 - Class II, June 16, 2025
Recall Summary
| Recall Number | Z-2166-2025 |
| Classification | Class II - Moderate risk |
| Date Initiated | June 16, 2025 |
| Status | Ongoing |
| Voluntary | Voluntary: Firm initiated |
Recalling Firm
| Firm | CooperVision, Inc. |
| Location | Scottsville, NY |
| Product Type | Devices |
| Quantity | 827 units |
Product Description
Biofinity Toric Multifocal Contact Lens
Reason for Recall
Lens blisters may have an incomplete or leaking seal which may render them unsterile.
Distribution Pattern
Worldwide distribution - US Nationwide and the countries of Brazil, Canada, Honduras, and Mexico.
Lot / Code Information
Carton Lot Numbers: RB0682365, RB0684301, RB0684305, RB0684311, RB0684313, RB0684317, RB0684321, RB0684325, RB0684335, RB0684506, RB0684575, RB0684582, RB0684653, RB0684657, RB0684659, RB0684663, RB0684664, RB0684667, RB0684668, RB0684669, RB0684670, RB0684673, RB0684674, RB0684676, RB0684682, RB0686359, RB0687092, RB0687368, RB0687370, RB0687547, RB0687582, RB0687586, RB0687665, RB0687693, RB0687797, RB0687800, RB0687801, RB0687802, RB0687803, RB0687807, RB0687812, RB0687822, RB0687893, RB0687897, RB0687904, RB0687908, RB0687910, RB0687922, RB0688105, RB0688107, RB0688109, RB0688113, RB0688117, RB0688121, RB0688128, RB0688130, RB0688145, RB0688147, RB0688151, RB0688163, RB0688170, RB0688174, RB0688269, RB0688298, RB0688300, RB0688305, RB0688307, RB0688320, RB0688322, RB0688343, RB0688492, RC1756323, RC1759660, RC1759663, RC1759931, RC1759947, RC1759965, RC1759967
Other Recalls from CooperVision, Inc.
| Recall # | Classification | Product | Date |
|---|---|---|---|
| Z-2606-2025 | Class II | MyDay Toric, stenfilcon A) Contact Lens. Model/... | Aug 22, 2025 |
| Z-2608-2025 | Class II | Voyant 1-Day Premium Toric, (stenfilcon A) cont... | Aug 22, 2025 |
| Z-2607-2025 | Class II | Sofmed Breathables, (stenfilcon A) contact lens... | Aug 22, 2025 |
| Z-2165-2025 | Class II | Biofinity XR Toric Contact Lens | Jun 16, 2025 |
| Z-1455-2025 | Class II | Brand Names: MyDay Toric, LensCrafters One Day ... | Feb 27, 2025 |
Frequently Asked Questions
Sterility recalls for medical devices vary in severity. If you have already had a procedure using a potentially non-sterile device, contact your healthcare provider immediately, you may need monitoring for signs of infection. Symptoms to watch for include fever, redness or swelling at the surgical site, unusual pain, or discharge. For devices that have not yet been used, they should be quarantined and returned to the manufacturer per the recall notice. Non-sterile implants can cause serious infections; early detection and treatment are critical.
Class I recalls indicate a reasonable probability of serious adverse health consequences or death from the defect. Class II recalls involve products that may cause temporary or medically reversible adverse health consequences, or where serious consequences are remote. Class III recalls cover products not likely to cause any adverse health consequences, typically involving technical regulatory violations. The classification guides urgency, Class I recalls require immediate action, while Class III may simply involve returning a product or acknowledging a labeling change. Always read the specific recall notice for recommended patient actions.
Report problems with medical devices to the FDA through MedWatch at 1-800-FDA-1088 or online at FDA.gov/safety/medwatch. Healthcare facilities are required by law to report device-related serious injuries and deaths. Patients and consumers can also report voluntarily. Include the device name, manufacturer, model number, and a description of the problem and any patient outcome. Reports from patients and clinicians help the FDA identify emerging safety signals and may trigger investigations that lead to recalls of dangerous devices.
What Should You Do?
Stop using this device if you are affected by this recall. Contact your healthcare provider and the manufacturer immediately for guidance. Report adverse events to FDA MedWatch.